A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 2134
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SD
Long Form : stable disease
No. Year Title Co-occurring Abbreviation
2020 A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. AGC, CERs, ICERs, OS, PFS
2020 Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. CI, EGFR, NSCLC, OS, PFS, PR, TKI
2020 Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). DLTs, EWS, RP2D, TMZ
2020 Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). CPS, IHC, TRAE
2020 Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). CR, CTCAE, DCR, EAP, irAEs, NSCLC, ORR, OS, PD, PFS, PR, RECIST
2020 Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. AUCs, CR, CT, DCA, HCC, NFH, PD, PR, SYUCC, TACE, ZHHAJU
2020 Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. CB
2020 Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis. AEs, HFS, PFS, PR, RR-DTC, WS
2020 [Application of endoscopic tattooing with carbon nanoparticlet in the treatment for advanced colorectal cancer]. ACRC, CR, PD, PR
10  2019 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. CR, DS, HL, PD, PR
11  2019 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. CT, F-FDG, PD, PR
12  2019 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. NETs, PD, PFS, PR
13  2019 A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. LCH, PD
14  2019 A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. CRC, DLTs, EGFR, MTD, PR
15  2019 A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. CB, CR, CTCAE, EORTC, LC, MPR-OC, ORR, PR, PTV, RTOG, SBRT
16  2019 A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy. mRCC, OS, PD, PR, RCC, TTP
17  2019 A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. CI, DCR, mTOR, mTORC1, NET, PR, SSA
18  2019 A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). HMA, MDS
19  2019 A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. DL, Inf.U, PR, rec
20  2019 A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. CPK, DLTs, GIST, OS, PFS, TEAE, TKIs
21  2019 A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. DLT, GD, GDC, Gr, MTD, PR, RPTD, TEAEs
22  2019 A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors. GC, HCC, TEAE
23  2019 A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. CHOAnome, DL, DLT, GBM, HGG, PR
24  2019 A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. CR, OS, PBLs, PFS, PR, RCR, SIG
25  2019 A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. AE, CR, DLT, MR, PD, PR, VGPR
26  2019 A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. AEs, MTD, mTOR, NSCLC, PFS, PR
27  2019 A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. DLT, FGF, GIST
28  2019 A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. AE's, CI, DDLS, DSRCT, LMS, MLS, ORRs, PFS, PR, SS, STS
29  2019 A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. CR, HMAs, MDS, PR
30  2019 A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). CI, MPM, OS, PFS-6, PR
31  2019 A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. ASPS, CI, ORR, OS, PET, PFS, PR
32  2019 A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. AEs, CR, ECOG, HN, mFUP, mOS, mPFS, PR, SGC
33  2019 A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. CBR, SINE, TNBC
34  2019 A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. CR, OS, PR, SBRT, UC
35  2019 A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer. CBR, CBR, CR, DCR, HIFU, ORR, OS, PFS, PR
36  2019 Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. BID, Choi, IQR, M-SFT, ORR, OS, PFS, PR, RECIST, SFT
37  2019 ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. CR, HCC, OS, PD, PR, VEGF, vWF, VWF
38  2019 An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. ECOG, HCC, MTD, PFS, Plk1, PR, siRNA
39  2019 Analysis of factors related to recurrence of paediatric hepatoblastoma - a single Centre retrospective study. AFP, PR, PRETEXT, RFS
40  2019 Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. CI, OS, PFS, PR
41  2019 Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. AEs, CI, DCR, PR, RECIST, SCLC
42  2019 Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. CI, DCR, HBV, HCC, ORR, OS, PD, PR, TTP
43  2019 Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study. NSCLC, ORR, PD, PR
44  2019 Assessment of spatial tumor heterogeneity using CT growth patterns estimated by tumor tracking on 3D CT volumetry of multiple pulmonary metastatic nodules. CT
45  2019 Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population. AUC, CR, DHPLC, ESCC, LNM, PD, PFS, PR, ROC
46  2019 Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. CAR, CRs, CRS, DLBCL, PET, PR
47  2019 Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images. CRPC, MVol, PD, PR, PSA, SVol
48  2019 Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control. CIRT, CR, DPFS, IMRT, LC, NPC, OS, PR
49  2019 Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. CR, DEE, HCC, mRECIST, PD, PR
50  2019 Carbon ions therapy as single treatment in chordoma of the sacrum. Histologic and metabolic outcome studies. CIRT, LC, OS, PFS, PR, SC
51  2019 Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS). ASPS, PR, RECIST, VEGF
52  2019 Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. HI, IPSS, MDS, WPSS
53  2019 Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI. CR, DF, MRI, MTX, PD, PFS, PR, VNL
54  2019 Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis. CEA, CR, CYFRA21-1, PD, PR
55  2019 Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. CR, DCR, DDGP, EBV, ORR, OS, PD, PFS, PR
56  2019 Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients. ---
57  2019 Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform. GBM, miR, PD, PR, qPCR
58  2019 Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. CR, FFPE, ICI, OS, PD-1, PD-L2, PFS, PR, QIF, RT-qPCR, RUO
59  2019 Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. CR, NHL, PD, PR, RIT, SPD, SUV
60  2019 Concurrent Bronchial Artery and Posterior Inferior Cerebellar Artery Microcatheter Interventional Chemotherapy for Adenocarcinoma of the Lung with Solitary Cerebellar Metastasis. CBP, CR, DCR, ORR, PD, PR
61  2019 Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. ADA, PD, PD-1, PR
62  2019 Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety. ALK, CR, DCR, NSCLC, ORR, PR
63  2019 CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study. PD, PR
64  2019 Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib. CCK-8, CDKN2B, HCC, PD, PR, RT-qPCR, SP
65  2019 Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. CR, PD, PR, TLT
66  2019 Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? CR, HR, MBC, OS, PD, PFS, PR
67  2019 Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms? HD, LD, PanNENs, PD, PR
68  2019 Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. cfDNA, MRD, MS, NB, PR
69  2019 Dysphagia predict the response to second cycle neoadjuvant chemotherapy in first cycle no response esophageal carcinoma. CI, CT, ESCC, NAC, OR, PD
70  2019 Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. BMAs, CR, CT, MDA criteria, NRS, PD, PR, RT
71  2019 Effect of oxaliplatin combined with 5-fluorouracil on treatment efficacy of radiotherapy in the treatment of elderly patients with rectal cancer. CR, DCR, PD, PR, RR
72  2019 Effects of cyclophosphamide combined with prednisone on TNF-alpha expression in treatment of patients with interstitial lung disease. CR, DLCO, FVC, ILD, SGRQ
73  2019 Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. OS, PD, PFS, PPS, PR, RR-DTC, TKIs
74  2019 Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. ACC, AE, mTKI, PR, RR
75  2019 Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. AEs, CI, MTCs, PR
76  2019 Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. RCC, VEGFR
77  2019 Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study. aNSCLC, CR, DCR, EC, EGFR, OS, PD, PFS, PR
78  2019 Efficacy of neoadjuvant chemotherapy and Annexin A3 expression in breast cancer. ANXA3, BC, CR, NAC, PD, PR
79  2019 Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer. CR, GC, PR, QOL
80  2019 Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. BR, EORTC, Ga68-PSMA PET-CT, MDA, PCa, PD, PR, PRLT, PSMA, RECIST 1.1
81  2019 Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. CB, CI, CR, EEC, OR, PR
82  2019 Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma. CR, lncRNAs, LUAD, LUSC, NSCLC, PD, PR, RFS, SUMO1, SUMO1P3
83  2019 Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. NETs, OS, PCC, PFS, PGL, PR, PRRT
84  2019 Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. ECOG, HBOT, MSCT, NSCLC, OS, PD, PFS
85  2019 Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. CR, MIBC, NAC, PD, RC, SNd, SNs
86  2019 First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. AEs, DCR, MPC, OS, PFS
87  2019 First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. mTOR, PK, PR
88  2019 Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison. cfDNA, EGFR, NSCLC, PR, TKIs
89  2019 Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. mCRC, PD, PR, RAS-M
90  2019 Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature. ---
91  2019 Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. AUC, DCB, ICIs, NDB, PD, PR, SCNA, TMB, WES
92  2019 Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. CR, DCR, DSA, FUDR, HAI, mOS, ORR, PR
93  2019 High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin. CR, CSCC, FIGO, PR, VEGF
94  2019 High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). AE, CR, DCR, HSV-1, ORR, PD, PR, T-VEC
95  2019 Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT. CR/PR, dNLR, HPD, ICI, NSCLC, PD
96  2019 Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. BED, CR, HCC, HFRT, IVC, IVC, PD, PR, RA, TT
97  2019 Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. CHT, CR, ES-SCLC, IMRT, OS, PFS, PR, TRT
98  2019 Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. CR, HCC, mRECIST, OR, PD, PR, TACE, TGR
99  2019 Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. CR, MHC, NK, PD, PR
100  2019 Intravoxel incoherent motion (IVIM) for response assessment in patients with osteosarcoma undergoing neoadjuvant chemotherapy. ADC, DWI, IVIM, NACT, PD, PR